
14. List of publications and citation metrics

Citation metrics

Total number of publications indexed in MEDLINE: 136

H-Index: 25

Scientific publications in international journals mentioned in the Social Science Citation Index, Science Citation Index or Arts & Humanities Citation Index [NB: JIF = Journal Impact Factor in the year of publication]

1. **Kotz D**, Kastaun S. Do people know that cigarette filters are mainly composed of synthetic material? A representative survey of the German population (the DEBRA study). *Tobacco control*. 2020 April 17 [online first]. [JIF 6.221]
2. Kastaun S, Hildebrandt J, **Kotz D**. Electronic Cigarettes to Vaporize Cannabis: Prevalence of Use and Associated Factors among Current Electronic Cigarette Users in Germany (DEBRA Study). *Substance Use & Misuse*. 2020:1-7. [JIF 1.381]
3. **Kotz D**, Batra A, Kastaun S. Smoking Cessation Attempts and Common Strategies Employed. *Dtsch Arztebl International*. 2020;117(1-2):7-13. [JIF 4.469]
4. Kastaun S, **Kotz D**. Should advertising for electronic cigarettes and heated tobacco products be banned in Germany? Results of a representative survey (DEBRA study). *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz*. 2019 Sep 16 [Epub ahead of print]. [JIF 0.945]
5. Boeckmann M, Warsi S, Noor M, [...] **Kotz D**. Health worker and patient views on implementation of smoking cessation in routine tuberculosis care. *NPJ Primary Care Respiratory Medicine*. 2019;29(1):34. [JIF 2.820]
6. Kastaun S, **Kotz D**, Brown J, Shahab L, Boeckmann M. Public attitudes towards healthcare policies promoting tobacco cessation in Germany: results from the representative German study on tobacco use (DEBRA study). *BMJ Open*. 2019;9(8):e026245. [JIF 2.376]
7. Kastaun S, Leve V, Hildebrandt J, [...] **Kotz D**. Effectiveness of training general practitioners to improve the implementation of brief stop-smoking advice in German primary care: study protocol of a pragmatic, 2-arm cluster randomised controlled trial (the ABCII trial). *BMC Family Practice*. 2019;20(1):107 [JIF 2.431]
8. Jackson S, **Kotz D**, West R, Brown J. Moderators of real-world effectiveness of smoking cessation aids: a population study. *Addiction* 2019 May 22 [Epub ahead of print] [JIF 6.851]
9. Kastaun S, **Kotz D**. Ärztliche Kurzberatung zur Tabakentwöhnung – Ergebnisse der DEBRA Studie [Brief physician advice for smoking cessation: Results of the DEBRA study]. *SUCHT*. 2019;65(1):34-41. [JIF -]
10. **Kotz D**, Kastaun S. E-Zigaretten und Tabakerhitzer: repräsentative Daten zu Konsumverhalten und assoziierten Faktoren in der deutschen Bevölkerung (die DEBRA-Studie). *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz*. 2018 Nov;61(11):1407-1414 [JIF -]
11. **Kotz D**, Böckmann M, Kastaun S. The use of tobacco, e-cigarettes, and methods to quit smoking in Germany—a representative study using 6 waves of data over 12 months (the DEBRA study). *Dtsch Arztebl Int*. 2018;115:235-242. [JIF 4.257]
12. Dogar O, Barua D, Boeckmann M, [...] **Kotz D** et al. The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients - protocol for a double-blind, placebo-controlled randomised trial. *Addiction*. 2018;113:1716–1726. [JIF 5.953]
13. Boeckmann M, **Kotz D**, Shahab L, Brown J, Kastaun S. German Public Support for Tobacco Control Policy Measures: Results from the German Study on Tobacco Use (DEBRA), a Representative National Survey. *International Journal of Environmental Research and Public Health*. 2018;15(4):696. [JIF 2.145]

14. Boeckmann M, Nohavova I, Dogar O, [...] **Kotz D**. Protocol for the mixed-methods process and context evaluation of the TB & Tobacco randomised controlled trial in Bangladesh and Pakistan: a hybrid effectiveness-implementation study. *BMJ Open*. 2018;8(3). [*JIF 2.369*]
15. van den Brand FA, Nagelhout GE, Reda AA, [...] **Kotz D**, van Schayck OC. Healthcare financing systems for increasing the use of tobacco dependence treatment. *Cochrane Database Syst Rev* 2017; 9 [*JIF 6.264*]
16. Slok AHM, Kotz D, van Breukelen G, [...] **Kotz D**. Assessment of Burden of COPD tool: evidence not perception. *European Respiratory Journal* 2017;50(1). [*JIF 8.332*]
17. van Rossem C, Spigt M, Viechtbauer W, Lucas AEM, van Schayck OCP, **Kotz D**. Effectiveness of intensive practice nurse counselling versus brief general practitioner advice, both combined with varenicline, for smoking cessation: a randomised pragmatic trial in primary care. *Addiction* 2017 Dec; 112(12):2237-2247 [*JIF 5.789*]
18. van Eerd EAM, Bech Risor M, Spigt M [...] **Kotz D**. Why do physicians lack engagement with smoking cessation treatment in their COPD patients? A multinational qualitative study. *NPJ Prim Care Respir Med*. 2017;27(1):41. [*JIF 1.447*]
19. van Eerd EAM, van Schayck OCP, Wesseling G, **Kotz D**. Predictors of long-term smoking cessation in patients with COPD: results from a randomised controlled trial. *European Respiratory Journal*. 2017;49(6). [*JIF 8.332*]
20. **Kotz D**, Viechtbauer W, Simpson CR, van Schayck OCP, West R, Sheikh A. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease. *Thorax* 2017 Oct; 72(10):905-911 [*JIF 8.121*]
21. Hummel K, Candel M, Nagelhout GE, Brown J, van den Putte B, **Kotz D**. et al. Construct and predictive validity of three measures of intention to quit smoking: Findings from the International Tobacco Control (ITC) Netherlands Survey. *Nicotine Tob Res*. *Nicotine Tob Res* 2018; 20:1101-1108 [*JIF 3.811*]
22. Kastaun S, Brown J, Brose LS [...] **Kotz D**. Study protocol of the German Study on Tobacco Use (DEBRA): a national household survey of smoking behaviour and cessation. *BMC Public Health*. 2017;17(1):378. [*JIF 2.209*]
23. Nwaru BI, Simpson CR, Sheikh A, **Kotz D**. External validation of a COPD prediction model using population-based primary care data: a nested case-control study. *Scientific Reports*. 2017;7:44702. [*JIF 5.228*]
24. Ubhi HK, **Kotz D**, Michie S, et al. A comparison of the characteristics of iOS and Android users of a smoking cessation app. *Transl Behav Med* 2017 [*JIF 2.189*]
25. Hummel K, Brown J, Willemsen MC, [...] **Kotz D**. External validation of the Motivation To Stop Scale (MTSS): findings from the International Tobacco Control (ITC) Netherlands Survey. *Eur J Public Health* 2017; 27:129-134 [*JIF 2.751*]
26. van den Brand FA, Nagelhout GE, Winkens B, Evers SMAA, **Kotz D** et al. The effect of financial incentives on top of behavioral support on quit rates in tobacco smoking employees: study protocol of a cluster-randomized trial. *BMC Public Health*. 2016;16(1):1-9. [*JIF 2.209*]
27. Slok AHM, Twellaar M, Jutbo L, **Kotz D** et al. 'To use or not to use': a qualitative study to evaluate experiences of healthcare providers and patients with the assessment of burden of COPD (ABC) tool. *Npj Primary Care Respiratory Medicine*. 2016;26:16074. [*JIF 1.447*]
28. van Eerd EAM, van der Meer RM, van Schayck OCP, **Kotz D**. Smoking cessation for people with chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*. 2016(8) [*JIF 6.103*]
29. Slok AHM, **Kotz D**, van Breukelen G, et al. Effectiveness of the Assessment of Burden of COPD (ABC) tool on health-related quality of life in patients with

- COPD: a cluster randomised controlled trial in primary and hospital care. *BMJ Open* 2016; 6 [JIF 2.562]
30. Ubhi HK, **Kotz D**, Michie S, et al. Comparative analysis of smoking cessation smartphone applications available in 2012 versus 2014. *Addictive Behaviors* 2016; 58:175-181 [JIF 2.798]
 31. Slok AHM, Bemelmans TCH, **Kotz D**, et al. The Assessment of Burden of COPD (ABC) Scale: A Reliable and Valid Questionnaire. *COPD: Journal of Chronic Obstructive Pulmonary Disease*. 2016:1-8. [JIF 2.673]
 32. Ubhi H, Michie S, **Kotz D**, et al. Characterising smoking cessation smartphone applications in terms of behaviour change techniques, engagement and ease-of-use features. *Translational Behavioral Medicine* 2015:1-8 [JIF 2.189]
 33. van Eerd EA, Risor MB, van Rossem CR, van Schayck OC, **Kotz D**. Experiences of tobacco smoking and quitting in smokers with and without chronic obstructive pulmonary disease-a qualitative analysis. *BMC Fam Pract* 2015; 16:164 [JIF 1.298]
 34. **Kotz D**, Viechtbauer W, Simpson C, et al. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. *The Lancet Respiratory Medicine* 2015; 3:761-768 [JIF 9.629]
 35. Viechtbauer W, Smits L, **Kotz D**, et al. A simple formula for the calculation of sample size in pilot studies. *J Clin Epidemiol* 2015 Nov;68(11):1375-9 [JIF 4.703]
 36. van Eerd EAM, van Rossem CR, Spigt MG, Wesseling G, van Schayck OCP, **Kotz D**. Do We Need Tailored Smoking Cessation Interventions for Smokers with COPD? A Comparative Study of Smokers with and without COPD Regarding Factors Associated with Tobacco Smoking. *Respiration* 2015;90(3):211-9 [JIF 2.924]
 37. van Rossem C, Spigt MG, Kleijnsen JRC, Hendricx M, van Schayck CP, **Kotz D**. Smoking cessation in primary care: exploration of barriers and solutions in current daily practice from the perspective of smokers and healthcare professionals. *European Journal of General Practice* 2015; 21: 111-117 [JIF -]
 38. van Rossem C, Spigt M, Smit ES, Viechtbauer W, Mijnheer, KK, van Schayck CP, **Kotz D**. Combining intensive practice nurse counselling or brief general practitioner advice with varenicline for smoking cessation in primary care: Study protocol of a pragmatic randomized controlled trial. *Contemporary Clinical Trials* 2015; 41:298-312 [JIF 2.502]
 39. Gommans EPAT, Evens P, Linssen CFM, van Dessel H, de Vries GJ, Dingemans AMC, **Kotz D**, Rohde, GGU. Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study. *Respiratory Medicine* 2015; 109:137-145 [JIF 2.917]
 40. Ubhi HK, Michie S, **Kotz D**, et al. A Mobile App to Aid Smoking Cessation: Preliminary Evaluation of SmokeFree28. *Journal of Medical Internet Research*; 2015; 17:e17 [JIF 4.669]
 41. Crutzen R, Viechtbauer W, Spigt M, **Kotz D**. Differential attrition in health behaviour change trials: a systematic review and meta-analysis. *Psychology & Health* 2014; 30:122-134 [JIF 1.950]
 42. **Kotz D**, Brown J, West R. Prospective cohort study of the effectiveness of varenicline versus single form nicotine replacement therapy for smoking cessation in the "real world". *BMC Public Health* 2014; 14:1163 [JIF 2.321]
 43. **Kotz D**, Brown J, West R. Prospective cohort study of the effectiveness of smoking cessation treatments used in the "real world". *Mayo Clinic Proceedings* 2014; 89:1360-1367 [JIF 5.810]
 44. Brown J, Beard E, **Kotz D**, et al. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. *Addiction* 2014; 109:1531-1540 [JIF 4.746]
 45. **Kotz D**, Simpson C, Viechtbauer W, et al. Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement

- therapy for smoking cessation: study protocol of a retrospective cohort study using the QResearch general practice database. *BMJ Open* 2014; 4 [JIF 1.583]
46. Slok A, in 't Veen J, Chavannes N, van der Molen T, Molken MPMH, Kerstjens H, Asijee G, Salome P, Holverda S, Dekhuijzen R, Schuiten D, van Breukelen G, **Kotz D**, van Schayck O. Effectiveness of the Assessment of Burden of Chronic Obstructive Pulmonary Disease (ABC) tool: study protocol of a cluster randomised trial in primary and secondary care. *BMC Pulmonary Medicine* 2014; 14:131 [JIF 2.489]
 47. van Schayck OCP, Horstman K, Vuurman E, de Wert G, **Kotz D**. Nicotine vaccination—does it have a future? *Addiction* 2014; 109:1223-1225 [JIF 4.894]
 48. Hoogsteder PH, **Kotz D**, van Spiegel PI, Viechtbauer W, van Schayck OC. Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. *Addiction* 2014; 109(8):1252-1259 [JIF 4.894]
 49. **Kotz D**, Simpson CR, Viechtbauer W, et al. Development and validation of a model to predict the 10-year risk of general practitioner-recorded COPD. *Npj Primary Care Respiratory Medicine* 2014; 24 [JIF 2.909]
 50. **Kotz D**, Brown J, West R. "Real-world" effectiveness of smoking cessation treatments: a population study. *Addiction* 2014; 109:491-499 [JIF 4.894]
 51. Brown J, **Kotz D**, Michie S, Stapleton J, Walmsley M, West R. How effective and cost-effective was the national mass media smoking cessation campaign 'Stoptober'? *Drug Alc Depend* 2014; 135:52-58 [JIF 3.141]
 52. **Kotz D**, Brown J, West R. Effectiveness of varenicline versus nicotine replacement therapy for smoking cessation with minimal professional support: evidence from an English population study. *Psychopharmacology* 2014; 231:37-42 [JIF 4.061]
 53. Hoogsteder PHJ, Merrebach MR, Otters MAF, van Schayck OCP, **Kotz D**. Exploring smokers' knowledge and expectations towards nicotine vaccination: a qualitative study. *Substance Use & Misuse* 2014; 49:87-94 [JIF 1.109]
 54. Been JV, **Kotz D**, van Schayck OCP. Poor reporting may infer poor science: lessons learned from asthma trials. *Primary Care Respiratory Journal* 2013; 22:388-390 [JIF 2.191]
 55. Reda AA, **Kotz D**, Biadgilign S. Adult tobacco use practice and its correlates in eastern Ethiopia: a cross-sectional study. *Harm Reduct J* 2013; 10:28 [JIF 1.485]
 56. Van Eerd E, Van der Meer RM, Reda AA, Van Schayck CP, **Kotz D**. Smoking cessation in smokers with chronic obstructive pulmonary disease (Protocol). *Cochrane Database of Systematic Reviews* 2013 [JIF 5.785]
 57. Crutzen R, Viechtbauer W, **Kotz D**, Spigt M. No differential attrition in randomized controlled trials published in general medical journals: a meta-analysis. *J Clin Epidemiol* 2013; 66:948-954 [JIF 4.271]
 58. **Kotz D**, Willemsen M, Brown J, et al. Light smokers are less likely to receive advice to quit from their GP than moderate-to-heavy smokers: a comparison of national survey data from the Netherlands and England. *Eur J Gen Pract* 2013; 19:99-105 [JIF 1.130]
 59. Cals JW, Mallen CD, Glynn LG, **Kotz D**. Should authors submit previous peer-review reports when submitting research papers? Views of general medical journal editors. *The Annals of Family Medicine* 2013; 11:179-181 [JIF 5.355]
 60. **Kotz D**, Cals JW, Tugwell P, et al. Introducing a new series on effective writing and publishing of scientific papers. *J Clin Epidemiol* 2013; 66:359-360 [JIF 4.271]
 61. **Kotz D**, Cals JW. Effective writing and publishing scientific papers—part I: how to get started. *J Clin Epidemiol* 2013; 66:397 [JIF 4.271]
 62. Cals JW, **Kotz D**. Effective writing and publishing scientific papers, part II: title and abstract. *J Clin Epidemiol* 2013; 66:585 [JIF 4.271]
 63. Cals JW, **Kotz D**. Effective writing and publishing scientific papers, part III: introduction. *J Clin Epidemiol* 2013; 66:702 [JIF 4.271]

64. **Kotz D**, Cals JWL. Effective writing and publishing scientific papers, part IV: methods. *J Clin Epidemiol* 2013; 66:817 [*JIF 4.271*]
65. **Kotz D**, Cals JWL. Effective writing and publishing scientific papers, part V: results. *J Clin Epidemiol* 2013; 66:945 [*JIF 4.271*]
66. Cals JWL, **Kotz D**. Effective writing and publishing scientific papers, part VI: discussion. *J Clin Epidemiol* 2013; 66:1064 [*JIF 4.271*]
67. **Kotz D**, Cals JWL. Effective writing and publishing scientific papers, part VII: tables and figures. *J Clin Epidemiol* 2013; 66:1197 [*JIF 4.271*]
68. Cals JWL, **Kotz D**. Effective writing and publishing scientific papers, part VIII: references. *J Clin Epidemiol* 2013; 66:1198 [*JIF 4.271*]
69. Cals JWL, **Kotz D**. Effective writing and publishing scientific papers, part IX: authorship. *J Clin Epidemiol* 2013; 66:1319 [*JIF 4.271*]
70. Cals JWL, **Kotz D**. Effective writing and publishing scientific papers, part X: choice of journal. *J Clin Epidemiol* 2014; 67:3 [*JIF 5.332*]
71. **Kotz D**, Cals JWL. Effective writing and publishing scientific papers, part XI: submitting a paper. *J Clin Epidemiol* 2014; 67:123 [*JIF 5.332*]
72. **Kotz D**, Cals JWL. Effective writing and publishing scientific papers, part XII: responding to reviewers. *J Clin Epidemiol* 2014; 67:243 [*JIF 5.332*]
73. **Kotz D**, Brown J, West R. Predictive validity of the Motivation To Stop Scale (MTSS): a single-item measure of motivation to stop smoking. *Drug Alc Depend* 2013; 128:15-19 [*JIF 3.383*]
74. Slenter RHJ, Sprooten RTM, **Kotz D**, et al. Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease. *Respiration* 2013; 85:15-26 [*JIF 2.258*]
75. Hoogsteder P, **Kotz D**, Viechtbauer W, et al. The efficacy and safety of a nicotine conjugate vaccine (NicVAX(R)) or placebo co-administered with varenicline (Champix(R)) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial. *BMC Public Health* 2012; 12:1052 [*JIF 2.000*]
76. **Kotz D**, Spigt M, Arts IC, et al. Use of the stepped wedge design cannot be recommended: A critical appraisal and comparison with the classic cluster randomized controlled trial design. *J Clin Epidemiol* 2012; 65:1249-1252 [*JIF 4.271*]
77. De Korte-de Boer D, **Kotz D**, Viechtbauer W, van Haren E, Grommen D, de Munter M, Coenen H, Gorgels APM, van Schayck OCP. Effect of smoke-free legislation on the incidence of sudden circulatory arrest in the Netherlands. *Heart* 2012; 98:995-999 [*JIF 4.223*]
78. Reda AA, **Kotz D**, Evers SMAA, van Schayck CP. Healthcare financing systems for increasing the use of tobacco dependence treatment. *Cochrane Database Syst Rev* 2012; Issue 6 [*JIF -*]
79. **Kotz D**. Possible Reasons for Elevated Carbon Monoxide Levels in Self-reported Ex-Smokers. *Nicotine and Tobacco Research* 2012; 14:900-901 [*JIF 2.801*]
80. **Kotz D**, Fidler J, West R. Very low rate and light smokers: smoking patterns and cessation-related behaviour in England, 2006-2011. *Addiction* 2012; 10:995-1002 [*JIF 4.014*]
81. Hukkinen M, Kaprio J, Broms U, Viljanen A, **Kotz D**, Rantanen T, Korhonen T. Heritability of lung function: A twin study among never-smoking elderly women. *Twin Research and Human Genetics* 2011; 14:401-7 [*JIF 1.994*]
82. **Kotz D**, Fidler JA, West R. Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications? *Nicotine and Tobacco Research* 2011; 13:793-9 [*JIF 2.801*]
83. **Kotz D**, Stapleton JA, Owen L, West R. How cost-effective is 'No Smoking Day'? *Tobacco Control* 2011; 20:302-304 [*JIF 3.852*]
84. Cals JWL, van Amelsvoort LGPM, **Kotz D**, Spigt MG. CONSORT 2010 statement – unfinished update? *Journal of Clinical Epidemiology* 2011; 64:579-82 [*JIF 2.956*]

85. **Kotz D**, van Schayck CP. Interpreting the diagnostic accuracy of tools for early detection of COPD. *Primary Care Respiratory Journal* 2011; 20:113-115 [JIF -]
86. **Kotz D**, Simpson CR, Sheikh A. Incidence, prevalence, and trends of general practitioner-recorded diagnosis of peanut allergy in England, 2001-2005. *Journal of Allergy and Clinical Immunology* 2011; 127:623-630 [JIF 9.165]
87. **Kotz D**, Glynn LG, Mallen CD, Cals JWL. Does Guinness travel well? *Journal of Food Science* 2011; 76:S121-S125 [JIF 1.601]
88. **Kotz D**, Wesseling G, Aveyard P, van Schayck CP. Smoking cessation and development of respiratory health in smokers screened with normal spirometry. *Respiratory Medicine* 2011; 105:243-249 [JIF 2.338]
89. Reda AA, **Kotz D**, Kocks JW, Wesseling G, van Schayck CP. Reliability and validity of the Clinical COPD Questionnaire and Chronic Respiratory Questionnaire. *Respiratory Medicine* 2010; 104:1675-1682 [JIF 2.338]
90. **Kotz D**, Vos R, Huibers MJH. Ethical analysis of the justifiability of labelling with COPD for smoking cessation. *Journal of Medical Ethics* 2009; 35:534-540 [JIF 1.103]
91. **Kotz D**, Fidler J, West R. Factors associated with the use of aids to cessation in English smokers. *Addiction* 2009; 104:1403-1410 [JIF 4.014]
92. **Kotz D**, Huibers MJH, West R, Wesseling GJ, van Schayck CP. What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD? *Patient Education and Counseling* 2009; 76:16-24 [JIF 1.792]
93. **Kotz D**, Wesseling GJ, Huibers MJH, van Schayck CP. Efficacy of confronting smokers with airflow limitation for smoking cessation. *European Respiratory Journal* 2009; 33:754-762 [JIF 5.349]
94. Yanbaeva D, Dentener M, Spruit M, Houwing-Duistermaat JJ, **Kotz D**, Lima Passos V, Wouters EFM. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. *BMC Medical Genetics* 2009; 10:23 [JIF 2.419]
95. **Kotz D**, West R. Explaining the social gradient in smoking cessation: it's not in the trying but in the succeeding. *Tobacco Control* 2009; 18: 43-46 [JIF 2.797]
96. Cals JWL, **Kotz D**. Researcher identification: the right needle in the haystack. *The Lancet* 2008; 371:2152-2153 [JIF 25.800]
97. **Kotz D**, Nelemans P, van Schayck CP, Wesseling GJ. External validation of a COPD diagnostic questionnaire in smokers. *European Respiratory Journal* 2008; 31:298-303 [JIF 5.076]
98. **Kotz D**, Huibers MJH, Vos R, van Schayck CP, Wesseling GJ. Principles of confrontational counseling in smokers with chronic obstructive pulmonary disease (COPD). *Medical Hypothesis* 2008; 70:384-386 [JIF 1.299]
99. **Kotz D**, van Litsenburg W, van Duurling R, van Schayck CP, Wesseling GJ. Smoking cessation treatment by Dutch respiratory nurses: reported practice, attitudes and perceived effectiveness. *Patient Education and Counseling* 2008; 70:40-49 [JIF 1.778]
100. **Kotz D**, van de Kant K, Jöbsis Q, van Schayck CP. Effects of tobacco exposure on lung health and pulmonary biomarkers in young, healthy smokers aged 12-25 years: a systematic review. *Expert Review in Respiratory Medicine* 2007; 1:403-418 [JIF -]
101. **Kotz D**, Wesseling GJ, Huibers MJH, van Schayck. Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. *BMC Public Health* 2007; 7:332 [JIF 1.600]
102. **Kotz D**, Wagena EJ, Wesseling GJ. Smoking cessation practices of Dutch general practitioners, cardiologists, and lung physicians. *Respiratory Medicine* 2007; 101:568-573 [JIF 2.086]

Editorials and Letters to the Editor [NB: JIF = Journal Impact Factor in the year of publication]

1. **Kotz D**, Viechtbauer W, Spigt M, Crutzen R. Submitting the original participant information letter as supplementary material of a trial report is useful and can be easily implemented. *Journal of Clinical Epidemiology*. 2020; 117: 151-153. [JIF 4.650]
2. Jackson SE, **Kotz D**, West R, Brown J. Reply to 'Smoke free, but dependent on nicotine' (Karam-Hage 2019). 2019 July 18 [online first]. [JIF 6.851]
3. Willemsen MC, Hipple Walters B, **Kotz D**, Bauld L. Recommendations on how to achieve tobacco-free nations in Europe. *Tobacco Prevention & Cessation*. 2019;5(July). [JIF -]
4. **Kotz D**, Viechtbauer W, Spigt M, Crutzen R. Details about informed consent procedures of randomized controlled trials should be reported transparently. *Journal of Clinical Epidemiology* 2019; 109:133-135. [JIF 4.245]
5. Batra A, **Kotz D**. Tobacco-related disorders – is there anything new? *SUCHT*. 2019;65(1):7-9. [JIF -]
6. Kastaun S, **Kotz D**. It's not the electronic cigarette, it's the nicotine causing hemodynamic problems: A commentary on the article by Franzen et al. *Vascular Medicine* 2018; 23:555-556. [JIF 2.393]
7. **Kotz D**, Brown J, West R. Questioning nicotine replacement therapy without behavioral support. *JAMA Internal Medicine* 2016; 176:863-864 [JIF 15.040]
8. **Kotz D**, Viechtbauer W, Simpson C, et al. Cardiovascular and neuropsychiatric risks of varenicline - Authors' reply. *The Lancet Respiratory Medicine* 2016; 4:e10 [JIF 9.629]
9. Cals JW, **Kotz D**. Literature review in biomedical research: useful search engines beyond PubMed. *Journal of Clinical Epidemiology* 2016; 71:115-117 [JIF 4.703]
10. **Kotz D**, Tugwell P, Knottnerus JA. How to promote transparency and accountability in clinical and behavioral research. *J Clin Epidemiol* 2016; 70:275 [JIF 4.703]
11. **Kotz D**, Viechtbauer W, Simpson C, et al. Cardiovascular and neuropsychiatric risks of varenicline: too good to be true? - Authors' reply. *Lancet Respir Med* 2015; 3:e40-42 [JIF 9.629]
12. **Kotz D**, Brown J, West R. In Reply--E-Cigs are Efficacious. Effectiveness of the e-cigarette and other aids to cessation in the "real world". *Mayo Clinic Proceedings* 2015; 90:417-418 [JIF 5.810]
13. **Kotz D**. Implementation of a new "opt-out" default for tobacco treatment is urgently needed but requires free access to evidence-based treatments. Comment on "It's time to change the default for tobacco treatment" by Richter & Ellerbeck. *Addiction* 2015; 110:387-388 [JIF 4.596]
14. **Kotz D**. Rigorous methodology is needed to analyse and interpret observational data on the use and effectiveness of smoking cessation aids. *Nicotine & Tobacco Research* 2014; 16:1537-1538 [JIF 2.477]
15. Viechtbauer W, **Kotz D**, Spigt M, et al. Response to Keriell-Gascou et al.: Higher efficiency and other alleged advantages are not inherent to the stepped wedge design. *J Clin Epidemiol* 2014; 67(7):834-836 [JIF 5.332]
16. **Kotz D**, Cals JW. Authors should consider reviewer comments on a rejected paper to improve their paper before submission to the next journal. *J Clin Epidemiol* 2014; 67: 830-831 [JIF 5.332]
17. **Kotz D**, Spigt M, Arts ICW, Crutzen R, Viechtbauer W. The stepped wedge design does not inherently have more power than a cluster randomized controlled trial. *J Clin Epidemiol* 2013; 66:1058-1060 [JIF 5.332]
18. **Kotz D**, Spigt M, Arts IC, et al. Researchers should convince policy makers to perform a classic cluster randomized controlled trial instead of a stepped wedge design when an intervention is rolled out. *J Clin Epidemiol* 2012; 65:1255-1256 [JIF 4.271]
19. de Korte-de Boer D, **Kotz D**, Viechtbauer W, et al. The Authors' reply to: Effect of smoke-free legislation on the incidence of sudden circulatory arrest in the Netherlands. *Heart* 2012;98:995e9. *Heart* 2012; 98:995-9 [JIF 4.223]

20. **Kotz D**, Fidler JA, West R. Estimating the rate of usage of varenicline and other medication for smoking cessation. *Addiction* 2011; 106:1868-9 [JIF 4.014]
21. **Kotz D**, van Schayck CP. What justifies a placebo-controlled trial of varenicline for smoking cessation in COPD patients? *Chest* 2011; 139:968-969 [JIF 6.360]
22. **Kotz D**, van Schayck OCP. Does screening of COPD deter smokers with normal lung function to quit smoking? *Primary Care Respiratory Journal* 2010; 19:402-402 [JIF -]
23. Cals JWL, **Kotz D**. An author identification system for vast coverage of researchers: *Science* 2009; 25 June [E-letter] [JIF -]
24. **Kotz D**, van Schayck CP, Huibers MJH, Wesseling GJ. Assessing the efficacy of spirometry for smoking cessation. *Thorax* 2007; 62:742 [JIF 6.064]
25. Spigt MG, **Kotz D**. A simple and valid tool distinguished efficacy from effectiveness studies. *Journal of Clinical Epidemiology* 2007; 60: 753-755 [JIF 2.440]

Scientific publication in national journals with referee system

1. Slok AHM, **Kotz D**, Chavannes NH, Snoeck-Stroband JB, Salomé PL, in 't Veen JCCM, van Schayck OCP. Use of the Assessment of Burden of COPD tool in practice [De Ziektelastmeter COPD als hulpmiddel in de praktijk]. *Huisarts en Wetenschap* 2017; 60(10):500-502.
2. Kastaun S, Leve V, Böckmann M, Reddemann O, **Kotz D**. Brief Advice in Primary Care According to the S3-Clinical Practice Guideline "Screening, Diagnosis and Treatment of Harmful and Addictive Tobacco Use" [Hausärztliche Kurzberatung anhand der S3-Leitlinienempfehlung "Screening, Diagnostik und Behandlung des schädlichen und abhängigen Tabakkonsums"]. *Zeitschrift für Allgemeinmedizin*. 2017; 93(5):210-215.
3. van Eerd E, **Kotz D**. Mobiele telefoon effectief bij stoppen met roken [Mobile phone-based interventions for smoking cessation]. *Huisarts en wetenschap* 2016; 59:577-577
4. van Schayck OCP, Slok AHM, **Kotz D**, et al. Effectiviteit van de "Ziektelastmeter COPD". Een clustergerandomiseerde gecontroleerde trial [Effectiveness of the Assessment of Burden of COPD (ABC) tool on health-related quality of life in patients with COPD: a cluster randomised controlled trial in primary and hospital care]. *Ned Tijdschr Geneesk* 2016; 160:D955
5. **Kotz D**, Kastaun S, Cals J. Neue ZEFQ Serie: Effektives Schreiben und Publizieren wissenschaftlicher Artikel. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2016; 110–111:93
6. **Kotz D**, Cals J. Effektives Schreiben und Publizieren wissenschaftlicher Artikel – Teil I: Anfangen zu Schreiben. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2016; 110–111:94-95
7. Cals J, **Kotz D**. Effektives Schreiben und Publizieren wissenschaftlicher Artikel – Teil II: Titel und Zusammenfassung (Abstract). *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2016; 112:66-67
8. Cals J, **Kotz D**. Effektives Schreiben und Publizieren wissenschaftlicher Artikel – Teil III: Einleitung. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2016; 113:76-77
9. **Kotz D**, Cals J. Effektives Schreiben und Publizieren wissenschaftlicher Artikel – Teil IV: Methoden. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2016; 115-116:93-94
10. **Kotz D**, Cals J. Effektives Schreiben und Publizieren wissenschaftlicher Artikel – Teil V: Ergebnisse. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen*. 2016; 117:71-72.
11. Cals J, **Kotz D**. Effektives Schreiben und Veröffentlichen wissenschaftlicher Artikel – Teil VI: Diskussion. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2016; 118–119:94-95

12. **Kotz D**, Cals J. Effectives Schreiben und Publizieren wissenschaftlicher Artikel – Teil VII: Tabellen und Abbildungen. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2017; 120:63-64
13. Cals J, **Kotz D**. Effectives Schreiben und Publizieren wissenschaftlicher Artikel – Teil VIII: Literaturhinweise. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 2017; 121:82-83.
14. Cals JWL, **Kotz D**. Effectives Schreiben und Publizieren wissenschaftlicher Artikel – Teil IX: Autorenschaft. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2017; 122:64-65
15. Cals J, **Kotz D**. Effectives Schreiben und Publizieren wissenschaftlicher Artikel – Teil X: Auswahl der Zeitschrift. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2017; 125:85-86
16. **Kotz D**, Cals J. Effectives Schreiben und Publizieren wissenschaftlicher Artikel – Teil XI: Einreichen eines Artikels. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2017; 126:94-95
17. **Kotz D**, Cals JWL. Effectives Schreiben und Publizieren wissenschaftlicher Artikel – Teil XII: Beantworten von Gutachterkommentaren. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2017; 127-128:88-89
18. **Kotz D**, Cals J. Schrijven en publiceren van een wetenschappelijk artikel. Deel 1: het begin. [Writing and publishing a scientific article. Part 1: how to start]. Huisarts Nu 2015; 44:170-171
19. Cals J, **Kotz D**. Schrijven en publiceren van een wetenschappelijk artikel. Deel 2: titel en abstract [Writing and publishing a scientific article. Part 2: title and abstract]. Huisarts Nu 2015; 44:172-173
20. Cals J, **Kotz D**. Schrijven en publiceren van een wetenschappelijk artikel. Deel 3: inleiding [Writing and publishing a scientific article. Part 3: introduction]. Huisarts Nu 2015; 44:214-215
21. **Kotz D**, Cals J. Schrijven en publiceren van een wetenschappelijk artikel. Deel 4: methoden [Writing and publishing a scientific article. Part 4: methods]. Huisarts Nu 2015; 44:216-217
22. **Kotz D**, Cals J. Schrijven en publiceren van een wetenschappelijk artikel. Deel 5: resultaten [Writing and publishing a scientific article. Part 5: results]. Huisarts Nu 2015; 44:262-263
23. Cals J, **Kotz D**. Schrijven en publiceren van een wetenschappelijk artikel. Deel 6: discussie [Writing and publishing a scientific article. Part 6: discussion]. Huisarts Nu 2015; 44:264-265
24. **Kotz D**, Cals J. Schrijven en publiceren van een wetenschappelijk artikel. Deel 7: tabellen en figuren [Writing and publishing a scientific article. Part 7: tables and figures]. Huisarts Nu 2016; 45:42-43
25. Cals J, **Kotz D**. Schrijven en publiceren van een wetenschappelijk artikel. Deel 8: referenties [Writing and publishing a scientific article. Part 8: references]. Huisarts Nu 2016; 45:44-45
26. **Kotz D**, Cals J. Schrijven en publiceren van een wetenschappelijk artikel. Deel 9: auteurschap [Writing and publishing a scientific article. Part 9: authorship]. Huisarts Nu. 2016; 45(2):90-91
27. Cals J, **Kotz D**. Schrijven en publiceren van een wetenschappelijk artikel. Deel 10: tijdschriftkeuze [Writing and publishing a scientific article. Part 10: choice of journal]. Huisarts Nu. 2016; 45(2):92-93
28. **Kotz D**, Cals J. Schrijven en publiceren van een wetenschappelijk artikel. Deel 11: een artikel indienen [Writing and publishing a scientific article. Part 11: submitting a paper]. Huisarts Nu. 2016; 45(3):138-139
29. Cals J, **Kotz D**. Schrijven en publiceren van een wetenschappelijk artikel. Deel 12: reageren op referentiencommentaar [Writing and publishing a scientific article. Part 12: responding to reviewers]. Huisarts Nu. 2016; 45(3):140-141
30. Willemsen MC, Croes EA, **Kotz D**, et al. De elektronische sigaret. Gebruik, gezondheidsrisico's, en effectiviteit als stopmethode. [Electronic cigarettes:

use, health risks, and effectiveness as a cessation method]. *Ned Tijdschr Geneeskd* 2015; 159:A9259

31. Hoogsteder P, **Kotz D**. Spreekuur: Stoppen met roken. [Consultation: Smoking cessation.] *Huisarts & Wetenschap*. *Huisarts en Wetenschap* 2012; 55:137
32. **Kotz D**. PEARLS: SMS bij stoppen met roken. [PEARLS: SMS for smoking cessation is effective]. *Tijdschrift voor Praktijkondersteuning* 2010; 5:81
33. **Kotz D**, Wesseling G, Huibers M, van Schayck CP. Rokers confronteren met luchtwebobstructie: helpt het bij stoppen-met-roken? [Confronting smokers with airflow limitation: does it help to stop smoking?]. *Tijdschrift voor Praktijkondersteuning* 2010; 34:6-12
34. **Kotz D**, Kaper J. Stoppen met roken in de huisartspraktijk. [Smoking cessation in general practice.] *Huisarts Nu* 2006, 35(3).

Scientific publication as a book or as a contribution to a book including proceedings

1. Cals J, **Kotz D**. Effective scientific writing and publishing. A quick guide in English, Dutch, and German. Maastricht: Maastricht University, 2019. ISBN: 9789090319216
2. **Kotz D**, Spigt MG, Cals JWL. A delicate taste of science. Discussions and dinners from the Journal Club Mesch. Maastricht: CAPHRI School for Public Health and Primary Care, 2009
3. **Kotz D**. The explanatory-pragmatic continuum of clinical trials. In: Kotz D, Spigt MG, Cals JWL, eds. A delicate taste of science. Discussions and dinners from the Journal Club Mesch. Maastricht: CAPHRI School for Public Health and Primary Care, 2009

Other publications

1. Kastaun S, Becker S, **Kotz D**. Wie effektiv ist die elektrische (E-)Zigarette bei der Tabakentwöhnung? *Pädiatrische Praxis* 2019; 91: 347-357
 2. Kastaun S, Becker S, **Kotz D**. Wie effektiv ist die elektrische (E-)Zigarette bei der Tabakentwöhnung? *Internistische Praxis* 2018; 59: 503-513
 3. Kastaun S, Becker S, **Kotz D**. Wie effektiv ist die elektrische (E-)Zigarette bei der Tabakentwöhnung? *Gynäkologische Praxis* 2018; 43: 703-513
 4. Kastaun S, Becker S, **Kotz D**. Wie effektiv ist die elektrische (E-)Zigarette bei der Tabakentwöhnung? *Tägliche Praxis* 2018; 60: 501-511
 5. Kastaun S, Becker S, **Kotz D**. Wie effektiv ist die elektrische (E-)Zigarette bei der Tabakentwöhnung? *Chirurgische Praxis* 2018; 84: 353-363
 6. Kastaun S, Leve V, Böckmann M, Reddemann O, **Kotz D**. Mit Kurzberatungen Rauchstopp umsetzen. *Hamburger Ärzteblatt* 2018; 72: 13-16
 7. Kastaun S, Funke C, **Kotz D**. Die elektrische (E-)Zigarette: Wirksames Mittel beim Ausstieg aus der Tabaksucht? [The electronic (e-)cigarette: an effective aid for quitting tobacco smoking?] *Luftpost* 2017 IV;8-12
 8. **Kotz D**. Therapieën voor stoppen-met-roken: effectiviteit onder normale omstandigheden in de algemene bevolking. ['Real-world' effectiveness of smoking cessation treatments: a population study.] *Tijdschrift voor Psychiatrie* 2014;56(6):413
 9. **Kotz D**, Wesseling G, Van Schayck CP. Vroegtijdig opsporen van COPD en de effecten op stoppen-met-roken. [Early detection of COPD and its effects on smoking cessation.]. *CAHAG Bulletin* 2009; 2
 10. **Kotz D**. Confronting smokers with previously undetected airflow limitation for smoking cessation. PhD thesis, Maastricht: Maastricht University Press, 2008 (ISBN: 978 90 5278 781 7)
 11. Van Schayck CP, **Kotz D**, Lammers E. Vragenlijst voor case-finding van COPD. [Questionnaire for case-finding of COPD.] *CAHAG Bulletin* 2006; 1.
-